Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
41 hedge funds and large institutions have $8.74M invested in Neos Therapeutics, Inc in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 9 closing their positions.
7% less funds holding
Funds holding: 44 → 41 (-3)
28% less capital invested
Capital invested by funds: $12.2M → $8.74M (-$3.47M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$93.6K |
| 2 |
SW
SlateStone Wealth
Jupiter,
Florida
|
+$42.1K |
| 3 |
VF
Virtu Financial
New York
|
+$16.4K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$10.8K |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$651K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$268K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$42.7K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$34K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$24.6K |
NEOS Hedge Fund Activity: Q3 2020 in Review
41 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q3 2020, worth a combined $8.74M — down 28% from $12.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of NEOS and 6 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $93.6K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $651K sold.
- 41 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q3 2020, down from 44 in Q2 2020.
- Funds reported $8.74M of Neos Therapeutics, Inc stock for Q3 2020, down 28% quarter-over-quarter.
- 6 funds opened new Neos Therapeutics, Inc positions in Q3 2020 and 9 closed out, a net change of -3 holders.
- The largest Neos Therapeutics, Inc buyer in Q3 2020 was Renaissance Technologies, an estimated $93.6K added.
- The largest Neos Therapeutics, Inc seller in Q3 2020 was Sphera Funds Management, an estimated $651K sold.
Based on aggregated 13F filings for Q3 2020.